| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs
BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces a commercial and clinical collaboration with Prof. Dr. Marianne Brodmann at the Medical University of Graz, Austria. Under the collaboration, Prof. Brodmann will adopt the Lumee oxygen platform technology in her practice of approximately 1,500 annual vascular procedures. In addition, as principal investigator (PI) of clinical studies that supported Lumee oxygen in its CE marking, Prof. Brodmann intends to integrate Profusa's platform technology in cases and clinical study programs.
Posted In: PFSA
